Kura Oncology Cost Of Revenue Over Time

KURA Stock  USD 8.86  0.08  0.89%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Kura Oncology Performance and Kura Oncology Correlation.
For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.
  
The current year's Cost Of Revenue is expected to grow to about 891.5 K.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.35)
Return On Assets
(0.29)
Return On Equity
(0.46)
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Cost Of Revenue Analysis

Compare Kura Oncology and related stocks such as Protagonist Therapeutics, Merus BV, and Replimune Group Cost Of Revenue Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
PTGX0.00.00.00.00.0247 K317 K57.6 M0.02.8 M2.8 M2.8 MM3.3 M6.5 M
MRUS10.1 M10.1 M10.1 M10.1 M18.6 M17.6 M1.5 M34.1 M224.2 K49.6 M57.3 M86.3 M12 M127.4 M133.8 M
REPL0.00.00.00.00.00.00.00.0148 K1.8 M4.1 M4.6 M2.4 M2.7 M2.2 M
KALV8.3 K8.3 K8.3 K8.3 K8.3 K0.012.7 K18.2 K35 K40.2 K651 K743 K802 K86.2 M0.0
CRNX5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M9.2 M24.5 M41.5 M57 M1.3 M1.4 M1.1 MM
GLUE72 K72 K72 K72 K72 K72 K72 K72 K72 K72 K537 K2.1 M8.6 M6.2 M3.9 M
ERAS310 K310 K310 K310 K310 K310 K310 K310 K310 K310 K540 K829 K2.6 M3.7 M3.9 M
COGT43.7 K43.7 K43.7 K43.7 K43.7 K43.7 K43.7 K43.7 K43.7 K43.7 K25.7 K147 K5.9 M3.6 M2.1 M
LRMR70 K70 K70 K70 K70 K70 K212 K188 K261 K78 K155 K326 K272 K311 K228.9 K
KNSA0.00.00.00.00.00.00.00.00.03.3 M3.8 M9.1 M47 M56.5 M59.4 M
DAWN155 K155 K155 K155 K155 K155 K155 K155 K155 K155 K155 K199 K531 K383 K348.7 K
INZY83 K83 K83 K83 K83 K83 K83 K83 K83 K83 K217 K1.1 M1.2 M1.3 M841.1 K
ZNTL111 K111 K111 K111 K111 K111 K111 K111 K111 K111 K160 K544 K1.4 M1.4 M798.6 K
SNDX0.00.00.00.00.021.1 M41.7 M64 M0.0456 K456 K456 K454 K12 K11.4 K

Kura Oncology and related stocks such as Protagonist Therapeutics, Merus BV, and Replimune Group Cost Of Revenue description

Cost of Revenue is found on Kura Oncology income statement and represents the costs associated with goods and services Kura Oncology provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

My Equities

My Current Equities and Potential Positions

Kura Oncology
KURA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 8.86
When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:
Check out Kura Oncology Performance and Kura Oncology Correlation.
For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Kura Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Kura Oncology technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Kura Oncology trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...